Cui J - Search Results

1

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).

Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Cui J, Li Y, Zhao H, Fang J, Xue J, Hu C, Sun P, Du Y, Zhou H, Wang S, Zhang W. Zhou C, et al. Among authors: cui j. J Thorac Oncol. 2021 Sep;16(9):1501-1511. doi: 10.1016/j.jtho.2021.04.011. Epub 2021 May 25. J Thorac Oncol. 2021. PMID: 34048947 Free article. Clinical Trial.

2

Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.

Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Cui J, et al. Int J Cancer. 2014 Jan 15;134(2):342-51. doi: 10.1002/ijc.28372. Epub 2013 Aug 5. Int J Cancer. 2014. PMID: 23825037

3

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.

Wu YL, Wang CL, Sun Y, Liao ML, Guan ZZ, Yang ZM, Zhou QH, Lu S, Cheng Y, Liu XQ, Zhang XC, Zhou C, Wang J, Zhou Q, Song Y, Han BH, Ma ZY, Yang F, Wang Q, Chuai SK, Shao Y, He W, Zhu G, Xiong L, Wang JJ, Chen KN, Zhang L, Mao WM, Ma SL, Feng JF, Yang XN, Xu L, Chen G, Zhao J, Song QB, Shen-Tu Y, Qiao GB, Yu D, Yu SY, Hu Y, Chen M, Chen GY, Fan Y, Zhang HL, Liang J, Zhu GY, Cui JW, Yang JJ, Zhao Q, Zhao MF, Lu Y, Chang JH, Li JL, Yang Y, Hu J, Gu CD, Zhang YC, Zhong WZ. Wu YL, et al. Among authors: cui jw. ESMO Open. 2017 Apr 4;2(Suppl 1):e000174. doi: 10.1136/esmoopen-2017-000174. eCollection 2017. ESMO Open. 2017. PMID: 28848676 Free PMC article. Review.

4

Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens.

Qian L, Dong YB, Zhao LL, Zhao HJ, Cui JW, Wang NY. Qian L, et al. Among authors: cui jw. Neoplasma. 2019 Mar 5;66(2):301-307. doi: 10.4149/neo_2018_180706N448. Epub 2018 Nov 23. Neoplasma. 2019. PMID: 30509107

5

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).

Song Y, Wu YL, Cao LJ, Chen JH, Ma ZY, Cui JW, Wang J, Liu HB, Ding JY, Hu M. Song Y, et al. Among authors: cui jw. Am J Clin Oncol. 2019 May;42(5):432-439. doi: 10.1097/COC.0000000000000538. Am J Clin Oncol. 2019. PMID: 30950859 Free PMC article. Clinical Trial.

6

First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.

Li LY, Wang H, Chen X, Li WQ, Cui JW. Li LY, et al. Chin Med J (Engl). 2019 Dec 5;132(23):2790-2794. doi: 10.1097/CM9.0000000000000536. Chin Med J (Engl). 2019. PMID: 31856049 Free PMC article.

7

Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.

Li W, Bai R, Qian L, Chen N, Zhao Y, Han F, Bai L, Li J, Yu Y, Cui J. Li W, et al. Among authors: cui j. Asia Pac J Clin Oncol. 2021 Apr;17(2):e40-e47. doi: 10.1111/ajco.13291. Epub 2020 Jan 19. Asia Pac J Clin Oncol. 2021. PMID: 31957251

8

Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Yang Y, et al. Among authors: cui j. Transl Lung Cancer Res. 2019 Dec;8(6):989-999. doi: 10.21037/tlcr.2019.12.23. Transl Lung Cancer Res. 2019. PMID: 32010577 Free PMC article.

9

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis.

Chen F, Chen N, Yu Y, Cui J. Chen F, et al. Among authors: cui j. Front Oncol. 2020 Jun 25;10:904. doi: 10.3389/fonc.2020.00904. eCollection 2020. Front Oncol. 2020. PMID: 32714857 Free PMC article.

10

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.

Wang Z, Zhao J, Ma Z, Cui J, Shu Y, Liu Z, Cheng Y, Leaw SJ, Wu Y, Ma Y, Tan W, Ma X, Zhang Y, Wang J. Wang Z, et al. Among authors: cui j. Lung Cancer. 2020 Sep;147:259-268. doi: 10.1016/j.lungcan.2020.06.007. Epub 2020 Jun 20. Lung Cancer. 2020. PMID: 32769013 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,674 results

Search Page

Filters